• Mohammad Nasser Hashemian, Hadi Z Mahrjerdi, Mehdi Mazloumi, Mona S Safizadeh, Yadollah Shakiba, Firouzeh Rahimi, Mohsen Afarideh, Mohamad Ali Zare, Mohammadreza Fallah Tafti, Bahram Bohrani Sepidan, Mohammad Ali Abtahi, and Seyed-Hossein Abtahi.
• Eye Research Center, Farabi Eye Hospital, Tehran University of Medical Sciences, Tehran, Iran.
• J Res Med Sci. 2017 Jan 1; 22: 16.

BackgroundTo compare the efficacy of subconjunctival administration of bevacizumab and different doses of sunitinib malate in reducing corneal neovascularization (CNV).Materials And MethodsIn this experimental study, central corneal cauterization was created in the right eye of fifty male Sprague-Dawley rats. On day 1 (1 week after cauterization), rats were randomly assigned into five treatment groups. Group control (n = 10) received subconjunctival injection of 0.02 ml of base saline solution. Group 1 (n = 10) received 0.02 ml of bevacizumab (25 mg/ml). Group 2, 3, and 4 (n = 10 for each group) were treated with 0.02 ml of sunitinib malate (10, 20, and 50 μg/ml, respectively). On days 1, 7, and 14, digital photographs of the cornea were taken, and the area of CNV was measured.ResultsDuring the 2-week follow-up, CNV area in treatment groups was less than in control group (P < 0.05). On day 7, corneal avascular area was highest in Group 3 at 63%. On day 14, the area of CNV in Groups 2 and 3 was less than in Group 1 (P = 0.031 and 0.011, respectively), but the difference between Groups 2 and 3 was not statistically significant (P = 0.552). The decreased CNV area on day 14 in Group 4 was significant in comparison to bevacizumab, but it was not significant on day 7 (P = 0.25 on day 7 and 0.002 on day 14).ConclusionSubconjunctival sunitinib malate is more effective than bevacizumab in regressing CNV. This effect is more prominent on day 14.

4 keywords...

hide…